Income StatementBalance SheetCash FlowSegments
Danaher logo

Danaher Business Segments

Business, geographic, and product segment breakdowns

Danaher generates $24.8B in annual revenue across 3 key segments: Biotechnology ($353.0M), Diagnostics ($621.0M), and Life Sciences ($165.0M). The company-wide operating margin is 19.21%. Based on the Q1 2026 filing.

Biotechnology (TTM)$353.0MDiagnostics (TTM)$621.0MLife Sciences (TTM)$165.0M
Latest FilingQ1 2026
Report Date2026-04-21
Market Cap$121.74B
P/E Ratio33.00
ROE7.11%

Products & Services

Sales

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Recurring revenue$5.1B$4.8B$5.0B$5.0B$5.3B$5.0B
Nonrecurring revenue$1.4B$925.0M$966.0M$1.0B$1.5B$920.0M

Geographic

Property, plant and equipment, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
All Other Countries$1.3B———$1.4B—

Sales

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North America$2.8B$2.6B$2.4B$2.6B$2.8B$2.5B
High-growth markets$1.9B$1.5B$1.7B$1.8B$2.0B$1.6B
Western Europe$1.5B$1.3B$1.5B$1.4B$1.7B$1.6B
Other developed markets$359.0M$278.0M$294.0M$316.0M$364.0M$284.0M

Earnings from continuing operations before income taxes

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Non Us$911.0M$815.5M$815.5M$815.5M$815.5M—

Business Segments

Adjustments due to finalization of purchase price allocations

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Diagnostics$0.0$0.0$0.0$0.0$0.0—
Life Sciences-$5.8M$2.3M$2.3M$2.3M$2.3M—

Intangible Amortization

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Biotechnology$213.0M$213.0M$228.0M$231.0M$230.0M$234.0M
Life Sciences$148.0M$149.0M$150.0M$154.0M$151.0M$152.0M
Diagnostics$47.0M$48.0M$48.0M$48.0M$47.0M$48.0M

Capital expenditures, gross

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Diagnostics$168.0M$115.0M$125.0M$157.0M$195.0M$144.0M
Biotechnology$117.0M$81.0M$80.0M$94.0M$115.0M$64.0M
Life Sciences$229.0M$48.0M$41.0M$40.0M$57.0M$27.0M

Depreciation

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Diagnostics$102.0M$100.0M$100.0M$101.0M$106.0M$102.0M
Life Sciences$44.0M$45.0M$45.0M$47.0M$48.0M$48.0M
Biotechnology$38.0M$34.0M$38.0M$38.0M$39.0M$40.0M

Goodwill

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Biotechnology$21.4B$22.3B$23.1B$23.1B$23.3B$23.0B
Life Sciences$12.3B$12.5B$12.9B$12.8B$12.9B$12.8B
Diagnostics$6.8B$6.8B$7.0B$7.0B$7.0B$7.0B

Goodwill, Foreign Currency Translation, Gain (Loss)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Diagnostics-$38.8M$56.8M$56.8M$56.8M$56.8M—
Life Sciences-$49.5M$135.5M$135.5M$135.5M$135.5M—

Identifiable assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Biotechnology$34.6B$36.1B$37.6B$37.3B$37.3B$36.7B
Life Sciences$23.2B———$23.1B$22.9B
Diagnostics$14.2B———$14.7B$14.7B

Operating Income (Loss)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Diagnostics$624.0M$718.0M$554.0M$665.0M$713.0M$674.0M
Biotechnology$508.0M$441.0M$531.0M$352.0M$540.0M$534.0M
Life Sciences$376.0M$201.0M-$239.0M$222.0M$336.0M$225.0M

Sales

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Diagnostics$2.6B$2.4B$2.3B$2.5B$2.7B$2.4B
Biotechnology$1.9B$1.6B$1.9B$1.8B$2.0B$1.8B
Life Sciences$2.0B$1.7B$1.8B$1.8B$2.1B$1.7B

Segment Reporting, Other Segment Item, Amount

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Diagnostics$1.8B$1.6B$1.6B$1.6B$1.9B$1.6B
Life Sciences$1.5B$1.3B$1.4B$1.4B$1.5B$1.3B
Biotechnology$1.1B$924.0M$1.1B$1.1B$1.2B$989.0M

Impairment Charges

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Life Sciences, Biotechnology and Diagnostics Segment—$32.5M$32.5M$32.5M$32.5M—

Goodwill impairment loss

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Life Sciences——$0.0———